This NIDDK-sponsored Core Center of Excellence in Hematology (CCEH) provides cost effective, quality assured resources and expertise that enable individual investigators to isolate stem / progenitor cells, mark them, alter their gene expression, and accurately detect and quantitate their progeny in vitro and in vivo. The original application funded in 1999, contained 5 cores which have to date served 90+ investigators, in 18 States and 4 countries. These resources have continuously evolved to adapt new functions that anticipate and meet the needs of the research base, as shown by the addition of a new core. Therefore the current application proposes 6 cores. Core A, the Administrative Core, directed by Dr Beverly Torok-Storb provides scientific and budgetary oversight for all core activities. Core B, now a National Core for Large-Scale Cell Processing directed by Dr Shelly Heimfeld, adapts and/or develops technologies to optimally harvest, isolate, cryopreserve and analyze defined populations of human, canine, and non-human primate cells harvested from blood and marrow. Core C, Clonal Analysis directed by Dr Mike Harkey, provides reagents and methods for tracking stem cell progeny. Core D, Vector Production directed by Dr Hans Peter Kiem, provides existing and develops improved viral vectors and vector production technologies for gene transfer into cells. Core E, Xenograft Models, under the direction of Dr Irv Bernstein provides xenografting for in vivo functional analysis of stem/progenitor cell populations. Core F, the developing Canine Cell and Molecular Resources Core, directed by Dr Patrick Paddison, is a new core that serves to enhance the value of the canine large animal model for preclinical in vivo testing of cells and reagents, with particular emphasis given to developing canine specific RNA interference technologies. Finally, Core A is also responsible for oversight of a charge-back system to generate program income. This program income is used to enhance the cores but also to fund the Pilot &Feasibility (P&F) Studies Program and the Enrichment Program. During the past five years 30 P&F grants were awarded and 27 speakers were sponsored. Both programs significantly impact the 40 member research base by stimulating and supporting new research directions and facilitating new collaborations. The NIH-sponsored Hematology-related support of the research base exceeds $25 million in direct costs annually. This represents more than 80% of all grants awarded to the research base.

Public Health Relevance

Procuring adequate numbers of hematopoietic stem cells for research and applying the latest technologies to this research are often outside the financial reach and expertise of individual investigators. The NIDDK-sponsored Core Centers provide a mechanism whereby collaborative groups of investigators share resources to reduce costs while providing high quality state-of-the-art technologies and speeding progress.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-G (O3))
Program Officer
Bishop, Terry Rogers
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
OhAinle, Molly; Helms, Louisa; Vermeire, Jolien et al. (2018) A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV. Elife 7:
Sorror, Mohamed L; Gooley, Ted A; Maclean, Kirsteen H et al. (2018) Pre-transplant expressions of microRNAs, comorbidities, and post-transplant mortality. Bone Marrow Transplant :
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Correnti, Colin E; Laszlo, George S; de van der Schueren, Willem J et al. (2018) Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia 32:1239-1243
Roesch, Ferdinand; OhAinle, Molly; Emerman, Michael (2018) A CRISPR screen for factors regulating SAMHD1 degradation identifies IFITMs as potent inhibitors of lentiviral particle delivery. Retrovirology 15:26
Hay, Kevin A; Turtle, Cameron J (2018) CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era. Immunotherapy 10:251-254
Yeung, Cecilia C S; McElhone, Scott; Chen, Xue Yan et al. (2018) Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol 31:569-580
Turtle, Cameron J; Hay, Kevin A; Hanafi, Laïla-Aïcha et al. (2017) Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol 35:3010-3020
Burwick, Nicholas; Zhang, Michael Y; de la Puente, Pilar et al. (2017) The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Leuk Res 55:23-32
Venkataraman, G M; Kennedy, L J; Little, M-T E et al. (2017) Thirteen novel canine dog leukocyte antigen-88 alleles identified by sequence-based typing. HLA 90:165-170

Showing the most recent 10 out of 267 publications